Skip to main content
Erschienen in: Strahlentherapie und Onkologie 2/2013

01.02.2013 | Original article

Intraoperative EBRT and resection for renal cell carcinoma

Twenty-year outcomes

verfasst von: F.A. Calvo, MD, PhD, C.V. Sole, MD, PhDc, R. Martinez-Monge, MD, I. Azinovic, MD, J. Aristu, MD, J. Zudaire, MD, J.L. Garcia-Sabrido, MD, J.M. Berian, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We report the outcomes of a multimodality treatment approach combining maximal surgical resection and intraoperative electron radiotherapy (IOERT) with or without external beam radiation therapy (EBRT) in patients with locoregionally (LR) recurrent renal cell carcinoma (RCC) after radical nephrectomy or LR advanced primary RCC.

Patients and methods

From 1983 to 2008, 25 patients with LR recurrent (n = 10) or LR advanced primary (n = 15) RCC were treated with this approach. Median patient age was 60 years (range, 16–79 years). Fifteen patients (60%) received perioperative EBRT (median dose, 44 Gy). Surgical resection was R0 (negative margins) in 6 patients (24%) and R1 (residual microscopic disease) in 19 patients (76%). The median dose of IOERT was 14 Gy (range, 9–15). Overall survival (OS) and relapse patterns were calculated using the Kaplan–Meier method.

Results

Median follow-up for surviving patients was 22.2 years (range, 3.6–26 years). OS and DFS at 5 and 10 years were 38% and 18% and 19% and 14%, respectively. LR control (tumor bed or regional lymph nodes) and distant metastases-free survival rates at 5 years were 80% and 22%, respectively. The death rate within 30 days of surgery and IOERT was 4% (n = 1). Six patients (24%) experienced acute or late toxicities of grade 3 or higher according to the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) v4.

Conclusion

In patients with LR recurrent or LR advanced primary RCC, a multimodality approach consisting of maximal surgical resection and IOERT with or without adjuvant EBRT yielded encouraging local control results, justifying further evaluation.
Literatur
1.
Zurück zum Zitat Esrig D, Ahlering TE, Lieskovsky G, Skinner DG (1992) Experience with fossa recurrence of renal cell carcinoma. J Urol 147:1491–1494PubMed Esrig D, Ahlering TE, Lieskovsky G, Skinner DG (1992) Experience with fossa recurrence of renal cell carcinoma. J Urol 147:1491–1494PubMed
2.
Zurück zum Zitat Tanguay S, Pisters LL, Lawrence DD, Dinney C (1996) Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 155:26–29PubMedCrossRef Tanguay S, Pisters LL, Lawrence DD, Dinney C (1996) Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol 155:26–29PubMedCrossRef
3.
Zurück zum Zitat Bruno JJ 2nd, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int 97:933–938PubMedCrossRef Bruno JJ 2nd, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int 97:933–938PubMedCrossRef
4.
Zurück zum Zitat Itano NB, Blute ML, Spotts B, Zincke H (2000) Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164:322–325PubMedCrossRef Itano NB, Blute ML, Spotts B, Zincke H (2000) Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164:322–325PubMedCrossRef
5.
Zurück zum Zitat Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12:206–212PubMed Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12:206–212PubMed
6.
Zurück zum Zitat Frydenberg M, Gunderson L, Hahn G et al (1994) Preoperative external beam radiotherapy followed by cytoreductive surgery and intraoperative radiotherapy for locally advanced primary or recurrent renal malignancies. J Urol 152:15–21PubMed Frydenberg M, Gunderson L, Hahn G et al (1994) Preoperative external beam radiotherapy followed by cytoreductive surgery and intraoperative radiotherapy for locally advanced primary or recurrent renal malignancies. J Urol 152:15–21PubMed
7.
Zurück zum Zitat Margulis V, McDonald M, Tamboli P et al (2009) Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 181:2044–2051PubMedCrossRef Margulis V, McDonald M, Tamboli P et al (2009) Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 181:2044–2051PubMedCrossRef
8.
Zurück zum Zitat Schrodter S, Hakenberg OW, Manseck A et al (2002) Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol 167:1630–1633PubMedCrossRef Schrodter S, Hakenberg OW, Manseck A et al (2002) Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol 167:1630–1633PubMedCrossRef
9.
Zurück zum Zitat Santos M, Ucar A, Ramos H et al (1989) Intraoperative radiotherapy in locally advanced carcinoma of the kidney: initial experience. Actas Urol Esp 13:36–40PubMed Santos M, Ucar A, Ramos H et al (1989) Intraoperative radiotherapy in locally advanced carcinoma of the kidney: initial experience. Actas Urol Esp 13:36–40PubMed
10.
Zurück zum Zitat National Cancer Institute (2011) Common toxicity criteria. Version 4.02, National Cancer Institute, Rockville National Cancer Institute (2011) Common toxicity criteria. Version 4.02, National Cancer Institute, Rockville
11.
Zurück zum Zitat Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
12.
Zurück zum Zitat Eble MJ, Stahler G, Wannenmacher M (1998) The intraoperative radiotherapy (IORT) for locally advanced and recurrent renal cell carcinomas. Strahlenther Onkol 174:30–36PubMedCrossRef Eble MJ, Stahler G, Wannenmacher M (1998) The intraoperative radiotherapy (IORT) for locally advanced and recurrent renal cell carcinomas. Strahlenther Onkol 174:30–36PubMedCrossRef
13.
Zurück zum Zitat Master VA, Gottschalk AR, Kane C, Carroll PR (2005) Management of isolated renal fossa recurrence following radical nephrectomy. J Urol 174:473–477 (discussion 477)PubMedCrossRef Master VA, Gottschalk AR, Kane C, Carroll PR (2005) Management of isolated renal fossa recurrence following radical nephrectomy. J Urol 174:473–477 (discussion 477)PubMedCrossRef
14.
Zurück zum Zitat Hallemeier CL, Choo R, Davis BJ et al (2012) Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for loco regionally recurrent or locorregionally advanced primary renal cell carcinoma. Int J Radiat Oncol Biol Phys 82:1938–1943PubMedCrossRef Hallemeier CL, Choo R, Davis BJ et al (2012) Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for loco regionally recurrent or locorregionally advanced primary renal cell carcinoma. Int J Radiat Oncol Biol Phys 82:1938–1943PubMedCrossRef
15.
Zurück zum Zitat Brown PD, Brown CA, Pollock BE et al (2008) Stereotactic radiosurgery for patients with “radioresistant” brain metastases. Neurosurgery 62(Suppl 2):790–801PubMed Brown PD, Brown CA, Pollock BE et al (2008) Stereotactic radiosurgery for patients with “radioresistant” brain metastases. Neurosurgery 62(Suppl 2):790–801PubMed
16.
Zurück zum Zitat Goyal LK, Suh JH, Reddy CA, Barnett GH (2000) The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 47:1007–1012PubMedCrossRef Goyal LK, Suh JH, Reddy CA, Barnett GH (2000) The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 47:1007–1012PubMedCrossRef
17.
Zurück zum Zitat Mori Y, Kondziolka D, Flickinger JC et al (1998) Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 42:581–589PubMedCrossRef Mori Y, Kondziolka D, Flickinger JC et al (1998) Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 42:581–589PubMedCrossRef
18.
Zurück zum Zitat Mori Y, Kondziolka D, Flickinger JC et al (1998) Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 83:344–353PubMedCrossRef Mori Y, Kondziolka D, Flickinger JC et al (1998) Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 83:344–353PubMedCrossRef
19.
Zurück zum Zitat Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferonalfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferonalfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef
20.
Zurück zum Zitat Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef
21.
Zurück zum Zitat Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef
22.
Zurück zum Zitat Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434PubMedCrossRef Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434PubMedCrossRef
23.
Zurück zum Zitat Hellenthal NJ, Underwood W, Penetrante R et al (2010) Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 184:859–864PubMedCrossRef Hellenthal NJ, Underwood W, Penetrante R et al (2010) Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 184:859–864PubMedCrossRef
24.
Zurück zum Zitat Pascau J, Santos Miranda JA, Calvo FA et al (2012) An innovative tool for intraoperative electron beam radiotherapy simulation and planning: description and initial evaluation by radiation oncologists. Int J Radiat Oncol Biol Phys 83:287–295 Pascau J, Santos Miranda JA, Calvo FA et al (2012) An innovative tool for intraoperative electron beam radiotherapy simulation and planning: description and initial evaluation by radiation oncologists. Int J Radiat Oncol Biol Phys 83:287–295
25.
Zurück zum Zitat Svedman C, Sandstrom P, Pisa P et al (2006) A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45:870–875PubMedCrossRef Svedman C, Sandstrom P, Pisa P et al (2006) A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45:870–875PubMedCrossRef
26.
Zurück zum Zitat Zelefsky MJ, Greco C, Motzer R et al (2012) Tumour control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 82:1744–1748PubMedCrossRef Zelefsky MJ, Greco C, Motzer R et al (2012) Tumour control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 82:1744–1748PubMedCrossRef
27.
Zurück zum Zitat Hines-Peralta A, Goldberg SN (2004) Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res 10:6328S–6334SPubMedCrossRef Hines-Peralta A, Goldberg SN (2004) Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res 10:6328S–6334SPubMedCrossRef
28.
Zurück zum Zitat Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(12 Suppl):2519–2528PubMedCrossRef Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(12 Suppl):2519–2528PubMedCrossRef
Metadaten
Titel
Intraoperative EBRT and resection for renal cell carcinoma
Twenty-year outcomes
verfasst von
F.A. Calvo, MD, PhD
C.V. Sole, MD, PhDc
R. Martinez-Monge, MD
I. Azinovic, MD
J. Aristu, MD
J. Zudaire, MD
J.L. Garcia-Sabrido, MD
J.M. Berian, MD
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 2/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-012-0272-3

Weitere Artikel der Ausgabe 2/2013

Strahlentherapie und Onkologie 2/2013 Zur Ausgabe

Mitteilungen der Fachgesellschaften

Mitteilungen der Fachgesellschaften

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.